Pharmacological and therapeutic effects of A 3 adenosine receptor agonists

Drug Discovery Today

Volumn 17, Issue 7-8, 2012, Pages 359-366

  Fishman, Pnina ^a   Bar Yehuda, Sara ^a   Liang, Bruce T ^b   Jacobson, Kenneth A ^c  

^a Can Fite BioPharma Ltd   (Israel)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; CF 102; CP 532903; CP 608039; DOXORUBICIN; FLUORINE 18; G PROTEIN COUPLED RECEPTOR; LJ 568; LUF 6000; MRS 3558; MRS 3581; MRS 5127; MRS 5147; N (3,4 DICHLOROPHENYL) 2 CYCLOHEXYL 1H IMIDAZO[4,5 C]QUINOLIN 4 AMINE; PLACEBO; RAZOXANE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BONE MARROW TOXICITY; BRAIN INJURY; BRAIN ISCHEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COLON CARCINOMA; CROHN DISEASE; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY EYE; ENTERITIS; EXPERIMENTAL MODEL; EYE DISEASE; GLAUCOMA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEPATITIS; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; ISCHEMIA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG; LYMPHOMA; MELANOMA; MOLECULAR RECOGNITION; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PSORIASIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLID TUMOR; TREATMENT OUTCOME; TUMOR XENOGRAFT; UVEITIS;

ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859265040     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.10.007     Document Type: Review

References (77)

1. 3 adenosine receptor Proc. Natl. Acad. Sci. 90 1993 10365 10369 (Pubitemid 23328313)
2. B.B. Fredholm Nomenclature and classification of adenosine receptors - an update Pharmacol. Rev. 63 2011 1 34
3. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells Clin. Cancer Res. 210 2004 5895 5901 (Pubitemid 39180971)
4. 3 adenosine receptor is highly expressed in tumor vs. normal cells: potential target for tumor growth inhibition Clin. Cancer Res. 10 2004 4472 4479 (Pubitemid 38878891)
5. 3 adenosine receptor is overexpressed in rheumatoid arthritis, psoriasis and Crohn's disease Cell. Immunol. 258 2009 115 122
6. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways Int. J. Oncol. 33 2008 287 295
7. P. Fishman The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis Arthritis Res. Ther. 8 2006 1 9
8. K. Varani Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes Br. J. Pharmacol. 160 2010 101 115
9. 3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells J. Mol. Cell. Cardiol. 49 2010 280 286
10. 3 adenosine receptors: novel ligands and paradoxical effects Trends Pharmacol. Sci. 19 1998 184 191 (Pubitemid 28255405)
11. E.C. Klaasse Internalization and desensitization of adenosine receptors Purinerg. Signal. 4 2008 21 37
12. 3 adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways Pharmacol. Res. 57 2008 303 311
13. 3 adenosine receptor targeting agents Expert Opin. Investig. Drugs 20 2011 757 768
14. 3 receptor agonists Bioorg. Med. Chem. 18 2010 7923 7930
15. 3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system J. Med. Chem. 52 2009 7580 7592
16. 3 receptor Nucl. Med. Biol. 35 2008 61 66
17. 3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics 2010 Springer 3 26
18. 3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers Biochem. Pharmacol. 82 2011 658 668
19. S.H. Kim Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria Br. J. Dermatol. 163 2010 977 985
20. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study Br. J. Pharmacol. 134 2001 116 126 (Pubitemid 32835474)
21. 3 antagonists Biochem. Biophys. Res. Commun. 232 1997 317 322 (Pubitemid 27216210)
22. 3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation Mol. Pharmacol. 62 2002 1373 1384 (Pubitemid 35403832)
23. S. Merighi Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line Br. J. Pharmacol. 134 2001 1215 1226 (Pubitemid 33097251)
24. B.C. Suh Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells Br. J. Pharmacol. 134 2001 132 142
25. S. Morello Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation Cancer Biol. Ther. 7 2008 278 0284
26. 3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis Inflamm. Bowel Dis. 12 2006 766 789 (Pubitemid 44253762)
27. 3 is a critical mediator in LPS-induced pulmonary inflammation Am. J. Physiol. Lung Cell. Mol. Physiol. 299 2010 L502 L512
28. 3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma Invest. Ophthalmol. Vis. Sci. 46 2005 2023 2034
29. 3 adenosine receptor in PBMNC of rheumatoid arthritis patients: Involvement of NF-κB in mediating receptor level J. Rheumatol. 34 2007 20 26 (Pubitemid 46106558)
30. A. Keibel Inflammation, microenvironment, and the immune system in cancer progression Curr. Pharm. Des. 15 2009 1949 1955
31. E.V. Ariztia The tumor microenvironment: key to early detection Crit. Rev. Clin. Lab. Sci. 43 2006 393 425 (Pubitemid 44596061)
32. 3 agonist Anticancer Res. 23 2003 2077 2083 (Pubitemid 36897167)
33. 3 adenosine receptor agonist potentiates natural killer cell activity Int. J. Oncol. 23 2003 1245 1249
34. 3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB Oncogene 23 2004 2465 2471 (Pubitemid 38520744)
35. G. Hasko Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice J. Immunol. 157 1996 4634 4640 (Pubitemid 126449386)
36. 3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice Eur. J. Pharmacol. 358 1998 261 268 (Pubitemid 28498186)
37. 6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis Eur. J. Pharmacol. 466 2003 323 329 (Pubitemid 36412095)
38. C. Szabó Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists Br. J. Pharmacol. 125 1998 379 387 (Pubitemid 28425204)
39. 3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents Exp. Hematol. 30 2002 1390 1398 (Pubitemid 35449795)
40. Y.W. Zhang Cardiomyocyte death in doxorubicin-induced cardiotoxicity Arch. Immunol. Ther. Exp. (Warsz) 57 2009 435 445
41. 3 adenosine receptor protects against doxorubicin-induced cardiotoxicity J. Mol. Cell. Cardiol. 33 2001 1249 1261 (Pubitemid 32579289)
42. 3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage Biochem. Pharmacol. 79 2010 180 187
43. 6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5′-N- methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel J. Pharmacol. Exp. Ther. 324 2008 234 243 (Pubitemid 350294150)
44. 2B receptor Mol. Pharmacol. 52 1997 846 860 (Pubitemid 27484178)
45. 3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs Am. J. Physiol. Heart Circ. Physiol. 285 2003 H607 H613
46. 6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits Circ. Res. 80 1997 800 809 (Pubitemid 27230054)
47. 6-(3-iodobenzyl)-adenosine-5′-N- methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta J. Pharmacol. Exp. Ther. 318 2006 124 131
48. 3 receptors in skeletal muscle ischemia and reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 293 2007 H3685 H3691
49. 3 adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils Mol. Pharmacol. 74 2008 685 696
50. 3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion Crit. Care 10 2006 R65
51. I. Matot Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion Anesthesiology 109 2008 269 278
52. 3 receptor agonist and cerebral ischemia: neuronal and glial effects Eur. J. Pharmacol. 367 1999 157 163 (Pubitemid 29106366)
53. H. Hu Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo Exp. Eye Res. 91 2010 425 432
54. 3 adenosine receptor agonist, in healthy young men Int. J. Clin. Pharmacol. Ther. 42 2004 534 542
55. E.D. Harris Rheumatoid arthritis: pathophysiology and implications for therapy N. Engl. J. Med. 322 1990 1277 1289
56. 3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial J. Rheumatol. 35 2008 1 7
57. E. Christophers Psoriasis - epidemiology and clinical spectrum Clin. Exp. Dermatol. 26 2001 314 320 (Pubitemid 34204344)
58. A. Asarch Th17 cells: a new paradigm for cutaneous inflammation J. Dermatol. Treat. 19 2008 259 266
59. R. Latkany Dry eyes: etiology and management Curr. Opin. Ophthalmol. 19 2008 287 291
60. A. Acera Inflammatory markers in the tears of patients with ocular surface disease Ophthalmic Res. 40 2008 315 321
61. I. Avni Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial Ophthalmology 117 2010 1287 2129
62. 3 adenosine receptor as a new target for cancer therapy and chemoprotection Exp. Cell Res. 269 2001 230 236 (Pubitemid 32907164)
63. 3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition J. Biol. Chem. 278 2003 42121 42130 (Pubitemid 37310479)
64. 3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity Neoplasia 11 2009 1132 1145
65. 3 adenosine receptor agonist CF101 Br. J. Cancer 89 2003 1552 1558 (Pubitemid 37386614)
66. 3 adenosine receptor enhances the chemotherapeutic effect of 5-flurouracil in a colon carcinoma murine model Neoplasia 7 2005 85 90 (Pubitemid 40209474)
67. 3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver J. Cell. Physiol. 226 2011 2438 2447
68. 3 adenosine receptor agonists in murine autoimmune arthritis models J. Rheumatol. 32 2005 469 476 (Pubitemid 40381417)
69. 3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis Clin. Exp. Rheumatol. 24 2006 400 4068
70. 3 adenosine receptor expression Arthritis Res. Ther. 8 2006 R169
71. S. Bar-Yehuda Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment Arthritis Rheum. 60 2009 3061 3071
72. 3 receptors in normal rat distal colon and experimental bowel inflammation Br. J. Pharmacol. 161 2010 856 871
73. 3 adenosine receptor agonist CF101 Int. J. Mol. Med. 28 2011 727 731
74. 3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 2006 R959 R969
75. 3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers Mol. Cancer Ther. 5 2006 685 692
76. M. Karin Nuclear factor-kappa B in cancer development and progression Nature 441 2006 431 436 (Pubitemid 44050137)
77. P. Zhai Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion Circ. Res. 109 2011 502 511